Paclitaxel

製品コードS1150 別名:NSC 125973

Paclitaxel化学構造

分子量(MW):853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

サイズ 価格(税別)  
JPY 15106.00
JPY 11620.00
JPY 44820.00

カスタマーフィードバック(4)

  • Characterization of nuclear damage by PARP as DNA damage repair marker. CLSM images of dual drug conjugated nanoparticle treatments to HeLa cells for 24 h at their respective IC50 drug dosages compared to nontreated control. Cells were stained with PARP-Alexafluor 488 antibody (green).

    ACS Appl Mater Interfaces, 2015, 7(14): 7584-98. Paclitaxel purchased from Selleck.

    Microscope image (406) magnification of U937 cells after exposure to SM-TNs. a) Untreated U937 cells. b) U937 cells treated with 200 nM, and 35 nM ODS empty shells. c) U937 cells treated with microcrystalline (free) Taxol prepared by sonicating Taxol in 20%H3PO4/0.8% SDS solution. d) U937 cells treated with 200 nM SM-TN. A SM-TN is seen in the middle of the picture. e) U937 cells treated with 35 nM SMTN.The nanowires are too small to see at this magnification, but their effect on the cells is clearly visible. Scale bar = 10 mm.

    RSC Adv 2011 1, 884-892. Paclitaxel purchased from Selleck.

  • Inhibitory effect of lenvatinib and paclitaxel on the proliferation of ATC cells. Cells were treated with the indicated concentrations of lenvatinib (A) and paclitaxel (B) for 48 h, followed by MTT assay to evaluate cell proliferation. IC50 values of these two drugs for each cell line were calculated using the Reed-Muench method

    Am J Cancer Res, 2017, 7(4):903-912. Paclitaxel purchased from Selleck.

    Western blot analysis of pPRAS40 (T246), pS6 (S240/S244), and pS6 (S235/S236) proteins in (A) HeyA8 cells and (B) SKOV3 cells treated with 0.37 μM or 10 μM paclitaxel in three-dimensional cell culture for 24 hours.

    PLoS One, 2016, 11(5):e0155052. . Paclitaxel purchased from Selleck.

製品安全説明書

Microtubule Associated阻害剤の選択性比較

生物活性

製品説明 Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
ターゲット
Microtubule (human endothelial cells) [1]
0.1 pM
体外試験

Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 NVWzOHAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\4coFKSzVyPUCuNFAxOjh5IN88US=> MnjtV2FPT0WU
LC-2-ad NHTId4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTTTWM2OD1yLkCwNFMyPyEQvF2= MXXTRW5ITVJ?
RL95-2 M1rKNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTBwMECwOlY5KM7:TR?= NF3ObJlUSU6JRWK=
MZ1-PC NETGXHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3:2c2lEPTB;MD6wNFA4OjlizszN MWfTRW5ITVJ?
TE-8 NIX1UXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHL6U3VKSzVyPUCuNFAyOTdizszN MWjTRW5ITVJ?
SW954 NFvXfWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwMECxNVkh|ryP MVfTRW5ITVJ?
TE-11 NF20TmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4ntZWlEPTB;MD6wNFEzOyEQvF2= M{D6bHNCVkeHUh?=
PSN1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfSTWM2OD1yLkCwNVMh|ryP MV;TRW5ITVJ?
MOLT-4 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwMECxOFkh|ryP M2\OWXNCVkeHUh?=
697 NHvKcXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fYZWlEPTB;MD6wNFE2KM7:TR?= Moe1V2FPT0WU
ETK-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPOWXRKSzVyPUCuNFAyPTJizszN NXvtbYpxW0GQR1XS
TE-10 NFXLdVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLKTWM2OD1yLkCwNVU1KM7:TR?= Ml3EV2FPT0WU
HUTU-80 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPLTWM2OD1yLkCwNVY5KM7:TR?= NWf4VWxuW0GQR1XS
NTERA-S-cl-D1 NHnrT2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\TeGlEPTB;MD6wNFIxQSEQvF2= NV[yc4R7W0GQR1XS
MFH-ino MmHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7WOoZKSzVyPUCuNFAzPjhizszN NUXZT5lpW0GQR1XS
IA-LM M3vmcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTBwMECyPEDPxE1? M{jKXnNCVkeHUh?=
MC116 M2fyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzvTVdKSzVyPUCuNFAzQDlizszN MVzTRW5ITVJ?
RKO MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TGUWlEPTB;MD6wNFI6QCEQvF2= MVTTRW5ITVJ?
MRK-nu-1 M{G2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTUWJZ5UUN3ME2wMlAxOjl7IN88US=> MlHPV2FPT0WU
VA-ES-BJ MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTBwMECzJO69VQ>? M3XjTHNCVkeHUh?=
KALS-1 Mmm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vkUWlEPTB;MD6wNFMxQCEQvF2= MUXTRW5ITVJ?
BB30-HNC NIq4W2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NID6d4xKSzVyPUCuNFA{OTRizszN Ml;2V2FPT0WU
ACN MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnFTWM2OD1yLkCwN|E3KM7:TR?= NX3hb4MzW0GQR1XS
TE-9 M{G2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvnVIhWUUN3ME2wMlAxOzJ4IN88US=> NXrCWJZ4W0GQR1XS
SIG-M5 M1vRSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLNTmpKSzVyPUCuNFA{OjdizszN MXjTRW5ITVJ?
no-10 NUD4W|JDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\NW2xvUUN3ME2wMlAxOzZ{IN88US=> MWDTRW5ITVJ?
EW-1 MlXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\MTWM2OD1yLkCwN|cyKM7:TR?= MlPHV2FPT0WU
SK-LMS-1 MnHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWj5V5JtUUN3ME2wMlAxPDBzIN88US=> NGewXlFUSU6JRWK=
GT3TKB MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEG2folKSzVyPUCuNFA1OzRizszN MYnTRW5ITVJ?
ES4 NELnUHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXH1N5dZUUN3ME2wMlAxPDR7IN88US=> NWL0fGVMW0GQR1XS
IMR-5 MnHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTBwMEC0OUDPxE1? NVrhTldDW0GQR1XS
NCI-H1648 NV[xVmVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwMEC0Olkh|ryP M2n3WHNCVkeHUh?=
MV-4-11 MkTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TVU2lEPTB;MD6wNFQ4PSEQvF2= M2eyXHNCVkeHUh?=
SK-UT-1 MoHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwMEC0PEDPxE1? M1PueHNCVkeHUh?=
NB13 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1v3[GlEPTB;MD6wNFQ6OSEQvF2= NHezcZJUSU6JRWK=
DJM-1 NX7pS3I2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPpWnhKSzVyPUCuNFA2OyEQvF2= NISzOVVUSU6JRWK=
ES8 NVH1Smh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HWV2lEPTB;MD6wNFU{QCEQvF2= NYXNNppQW0GQR1XS
TE-6 M37NXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwMEC1O{DPxE1? MXzTRW5ITVJ?
KS-1 Ml7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPEPHhzUUN3ME2wMlAxPTh{IN88US=> NI\TXVZUSU6JRWK=
TE-1 NEj3TXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwMEC2NFYh|ryP M4f3WnNCVkeHUh?=
ATN-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDlTWM2OD1yLkCwOlA6KM7:TR?= NXXGUFRIW0GQR1XS
A4-Fuk MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmP4TWM2OD1yLkCwOlEyKM7:TR?= NFe3bnRUSU6JRWK=
ALL-PO MkSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HoW2lEPTB;MD6wNFY{KM7:TR?= MmPEV2FPT0WU
BE-13 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwMEC2N|Yh|ryP MmfqV2FPT0WU
KM12 NG\3boRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXW2N4JwUUN3ME2wMlAxPjN5IN88US=> MlPTV2FPT0WU
NOS-1 M3H3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTBwMEC2OUDPxE1? MlPuV2FPT0WU
SW962 NHfuUINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwMEC2OlIh|ryP MmDWV2FPT0WU
OCUB-M M164Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwMEC2OlIh|ryP Ml7qV2FPT0WU
NCI-H510A MmTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfEeYM3UUN3ME2wMlAxPjZ3IN88US=> NHfxWG5USU6JRWK=
EW-16 NFvIPHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzwZlB[UUN3ME2wMlAxPjl2IN88US=> MXXTRW5ITVJ?
KGN MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrKOJhMUUN3ME2wMlAxPzF{IN88US=> Ml;RV2FPT0WU
LS-411N MmjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHr6cGdKSzVyPUCuNFA4OTdizszN MVfTRW5ITVJ?
Becker MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETKfGpKSzVyPUCuNFA4OiEQvF2= MV\TRW5ITVJ?
HC-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTyc3dKUUN3ME2wMlAxPzJzIN88US=> Ml\qV2FPT0WU
CESS NGDqOWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{frRWlEPTB;MD6wNFc{PyEQvF2= M3r2enNCVkeHUh?=
KURAMOCHI NUHXOVl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTBwMEC3OFgh|ryP NIntN29USU6JRWK=
TGBC24TKB MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvzZY5KSzVyPUCuNFA4PTJizszN MUTTRW5ITVJ?
SW982 NWezOYZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwMEC3OlYh|ryP MnLZV2FPT0WU
HCE-4 NXzmPJNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPQUVhCUUN3ME2wMlAxPzZ5IN88US=> NGnBXXRUSU6JRWK=
LOUCY NIjjeWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7pS2ZSUUN3ME2wMlAxPzd3IN88US=> NFjiflNUSU6JRWK=
8-MG-BA NFX6cpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLLb5hKSzVyPUCuNFA4QTZizszN NFu5WXBUSU6JRWK=
HT-144 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTMWWVwUUN3ME2wMlAxQCEQvF2= MXzTRW5ITVJ?
LXF-289 NXroOItST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLjT3ZKSzVyPUCuNFA5OThizszN NWfafFlXW0GQR1XS
RS4-11 MlfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYi3bpBsUUN3ME2wMlAxQDN4IN88US=> Mn3zV2FPT0WU
DEL M1PtZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXSWYtjUUN3ME2wMlAxQDR3IN88US=> MlXiV2FPT0WU
OCI-AML2 M1m0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjLd2I4UUN3ME2wMlAxQDV{IN88US=> NF7weJlUSU6JRWK=
CCRF-CEM M{\vc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\o[GlEPTB;MD6wNFg4OSEQvF2= MkjqV2FPT0WU
A388 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTBwMEC4O|Qh|ryP NGLscWRUSU6JRWK=
KNS-42 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPGTWM2OD1yLkCwPFkyKM7:TR?= NXrRV49oW0GQR1XS
OVCAR-4 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PxZWlEPTB;MD6wNFkxPCEQvF2= M{XyW3NCVkeHUh?=
NCI-H1355 NGrqSmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEezU|BKSzVyPUCuNFA6OTRizszN NIfsepBUSU6JRWK=
BL-70 NUHOWYlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmT5TWM2OD1yLkCwPVMh|ryP NWLKe4ttW0GQR1XS
BL-41 NX3UTmtXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMEC5N|Qh|ryP M4XydnNCVkeHUh?=
A101D MoK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrLPJBbUUN3ME2wMlAxQTZizszN MV\TRW5ITVJ?
HL-60 NVLRNGxKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXNZVhKSzVyPUCuNFA6PjZizszN MVPTRW5ITVJ?
COR-L279 NGHPUpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTBwMEC5PVkh|ryP NF3CV3RUSU6JRWK=
NCI-SNU-16 NGG3T|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYO0RpFmUUN3ME2wMlAyODB6IN88US=> MXHTRW5ITVJ?
Calu-6 M324U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{C4PWlEPTB;MD6wNVAyOiEQvF2= MmDTV2FPT0WU
SR M{jNSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojsTWM2OD1yLkCxNFI3KM7:TR?= MoPqV2FPT0WU
QIMR-WIL NF3p[HlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTBwMEGwN|Mh|ryP M2rMVHNCVkeHUh?=
LB647-SCLC NFe1XW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTBwMEGwOVEh|ryP M{XNeXNCVkeHUh?=
RPMI-8226 NWHoW5JET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTBwMEGxNFIh|ryP M2jT[nNCVkeHUh?=
SK-PN-DW NInBd4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGS5dVFKSzVyPUCuNFEyOTJizszN MXjTRW5ITVJ?
SF268 NUO5bW5uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vjemlEPTB;MD6wNVE2OSEQvF2= MUjTRW5ITVJ?
HD-MY-Z NEHPO3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwMEGxOlMh|ryP MW\TRW5ITVJ?
DOHH-2 MlHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFruUoxKSzVyPUCuNFEzODNizszN M2npZnNCVkeHUh?=
SCC-3 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIm0Z5VKSzVyPUCuNFEzODRizszN M1X4[XNCVkeHUh?=
ST486 NHzBOHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwMEGyNFQh|ryP MYPTRW5ITVJ?
NALM-6 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1r6ZmlEPTB;MD6wNVIyPCEQvF2= MYfTRW5ITVJ?
NCI-H1436 NFXiVWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3UPJlKSzVyPUCuNFEzOzFizszN M{XhRnNCVkeHUh?=
KE-37 M2jXVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13He2lEPTB;MD6wNVI{PCEQvF2= NWLYUIpxW0GQR1XS
RPMI-8402 NXSyRmpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPi[JhQUUN3ME2wMlAyOjV4IN88US=> MknLV2FPT0WU
RXF393 NIPtPYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTBTWM2OD1yLkCxNlU4KM7:TR?= MU\TRW5ITVJ?
KARPAS-45 NVXpZ2N{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH32UYNKSzVyPUCuNFEzPyEQvF2= MVXTRW5ITVJ?
HOP-62 NG\rPHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTBwMEGyO|Yh|ryP MUnTRW5ITVJ?
ES1 NFfzZVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTBwMEGyPFgh|ryP NXPWeWRmW0GQR1XS
L-363 MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3Ld|lxUUN3ME2wMlAyOzVzIN88US=> NEfMWJVUSU6JRWK=
GI-1 NX\pdYJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzxPYdKSzVyPUCuNFE{PzNizszN MmGzV2FPT0WU
CTV-1 MonSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7HTWM2OD1yLkCxOFc5KM7:TR?= NYrSZ3ZKW0GQR1XS
TE-5 Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTxTWM2OD1yLkCxOFk3KM7:TR?= MmP0V2FPT0WU
SNU-C2B NUfYVnpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHhOoFKSzVyPUCuNFE1QTZizszN NEnwXlJUSU6JRWK=
K-562 NFrlSFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXvTWM2OD1yLkCxOVE3KM7:TR?= MljPV2FPT0WU
SNB75 NFjjbYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWntSI4xUUN3ME2wMlAyPTRizszN MonwV2FPT0WU
MOLT-13 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfnN3ZKSzVyPUCuNFE3OzdizszN MlG2V2FPT0WU
LS-123 NWDJNI5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PyTWlEPTB;MD6wNVY3PCEQvF2= MomwV2FPT0WU
NCI-SNU-5 NGK3OJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{X5ZmlEPTB;MD6wNVcxOSEQvF2= NWrldpFMW0GQR1XS
Daudi NHnNd4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\wTWM2OD1yLkCxO|A5KM7:TR?= M{LGOnNCVkeHUh?=
A253 MmHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXn3PG8{UUN3ME2wMlAyPzN6IN88US=> MoTTV2FPT0WU
TGBC1TKB NGW0UmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH76Wo9KSzVyPUCuNFE4PTJizszN Mof1V2FPT0WU
SJSA-1 M3;HPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnLTWM2OD1yLkCxO|Y4KM7:TR?= MnK1V2FPT0WU
NCCIT NHfjZ2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHFTWM2OD1yLkCxO|Y6KM7:TR?= M4ixZnNCVkeHUh?=
NCI-H69 NEX3[HdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mny1TWM2OD1yLkCxO|c5KM7:TR?= NH\XZZJUSU6JRWK=
SH-4 NGDHfodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHYPJBKSzVyPUCuNFE5QTVizszN MkLQV2FPT0WU
HCC1187 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XySWlEPTB;MD6wNVkzPCEQvF2= MoPIV2FPT0WU
HCC1599 NX7Qdno6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTBwMEKwNkDPxE1? NV;PSIdNW0GQR1XS
ONS-76 Mo\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\hTWM2OD1yLkCyNFM3KM7:TR?= M163SXNCVkeHUh?=
KU812 MkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXwTWM2OD1yLkCyNFM6KM7:TR?= MoewV2FPT0WU
ML-2 MnfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwMEKwOFch|ryP NU\YdoFDW0GQR1XS
HCE-T M3HmVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDoTWM2OD1yLkCyNFkzKM7:TR?= NIjUdllUSU6JRWK=
NCI-H446 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTBwMEKxNVIh|ryP M1f4RnNCVkeHUh?=
RPMI-6666 NGXwVJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\ONHlpUUN3ME2wMlAzOTR7IN88US=> NV;kO2VSW0GQR1XS
MOLT-16 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTBwMEKxOVMh|ryP MWTTRW5ITVJ?
JiyoyeP-2003 NF\aWHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfPb25KSzVyPUCuNFIyPzZizszN NIj1NYpUSU6JRWK=
MHH-PREB-1 NYjOe2lbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofaTWM2OD1yLkCyNVkyKM7:TR?= M{nRPXNCVkeHUh?=
MC-CAR M4HxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELJRmpKSzVyPUCuNFI{OjZizszN NHT5UY5USU6JRWK=
BC-3 M3HYOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jSPGlEPTB;MD6wNlM1PCEQvF2= NHLmU|VUSU6JRWK=
KINGS-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjud5lsUUN3ME2wMlAzOzV3IN88US=> NXv6V4lnW0GQR1XS
PF-382 MluzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVy3e|FxUUN3ME2wMlAzOzd6IN88US=> M2DH[XNCVkeHUh?=
J-RT3-T3-5 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrBVYRKSzVyPUCuNFI{QDNizszN Mny4V2FPT0WU
SF539 Ml\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfybWpKSzVyPUCuNFI1ODFizszN NUHtcIJ5W0GQR1XS
LB831-BLC MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwMEK0PFUh|ryP NUS5NWdzW0GQR1XS
DMS-114 NIK3b5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;oXWNKSzVyPUCuNFI2ODJizszN M1HO[XNCVkeHUh?=
LB1047-RCC M{nLTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvwN5hZUUN3ME2wMlAzPTFizszN NXfSXFNmW0GQR1XS
LB771-HNC NH7xbGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkj6TWM2OD1yLkCyOVM1KM7:TR?= MVrTRW5ITVJ?
BB65-RCC NHX1VI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHOTWM2OD1yLkCyOVM1KM7:TR?= NH\YdIhUSU6JRWK=
BV-173 NIrpcphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LvcGlEPTB;MD6wNlU2PCEQvF2= MUjTRW5ITVJ?
ARH-77 NG\xNZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTBwMEK2NFEh|ryP MoLXV2FPT0WU
IST-MEL1 MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF22W3JKSzVyPUCuNFI3OjNizszN NWK1UlRYW0GQR1XS
NB1 NXTQUnF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwMEK2PFch|ryP MVrTRW5ITVJ?
EoL-1-cell NGLDW2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LpfGlEPTB;MD6wNlY5QCEQvF2= NWnnUXVDW0GQR1XS
KY821 M2XwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLTTWM2OD1yLkCyOlk4KM7:TR?= MVLTRW5ITVJ?
CMK NVLWbI1bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfXbI5DUUN3ME2wMlAzPzN2IN88US=> Ml31V2FPT0WU
NCI-H2126 M1Xuc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvwVG5KSzVyPUCuNFI4PjhizszN M1;uc3NCVkeHUh?=
NCI-H526 NHznWm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTBwMEK4PVEh|ryP NGXzSHNUSU6JRWK=
COLO-684 NX\Vc2VpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGf0RXVKSzVyPUCuNFI6ODhizszN M4T0W3NCVkeHUh?=
NCI-H747 NYC4[GtMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwMEK5N|Mh|ryP MV3TRW5ITVJ?
JAR MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEj3S|BKSzVyPUCuNFI6PDZizszN MVfTRW5ITVJ?
MEG-01 MnXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnr[INvUUN3ME2wMlAzQTd6IN88US=> MV7TRW5ITVJ?
MONO-MAC-6 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PrOWlEPTB;MD6wN|AzOyEQvF2= NWjHWHlVW0GQR1XS
IST-SL1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXhN2tKSzVyPUCuNFMxPDJizszN M1vKTHNCVkeHUh?=
CPC-N NEDKc|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDX[VRxUUN3ME2wMlA{ODd7IN88US=> MWjTRW5ITVJ?
NCI-H1963 M2PLbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwMEOxN|Eh|ryP NGnYUpRUSU6JRWK=
K052 NY\pUnVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYT4THdRUUN3ME2wMlA{OjR5IN88US=> NVywc21mW0GQR1XS
KM-H2 NGT5TJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknqTWM2OD1yLkCzN|A4KM7:TR?= NHG2[WJUSU6JRWK=
TE-12 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXKzXW4xUUN3ME2wMlA{OzB7IN88US=> Mn3FV2FPT0WU
TK10 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjETWM2OD1yLkCzN|U3KM7:TR?= NEPGSWNUSU6JRWK=
NMC-G1 MofwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnudmlFUUN3ME2wMlA{PDV{IN88US=> M2DTU3NCVkeHUh?=
no-11 NGSyT3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLJTWM2OD1yLkCzOFc5KM7:TR?= NVL4WFVsW0GQR1XS
NCI-H524 M2j6UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLrTWM2OD1yLkCzOVI6KM7:TR?= NYn6PI1uW0GQR1XS
MHH-CALL-2 M4HEVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTBwMEO1OlIh|ryP NWLhdVJsW0GQR1XS
GB-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vOfmlEPTB;MD6wN|Yh|ryP MnzQV2FPT0WU
OPM-2 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmntTWM2OD1yLkCzOlc{KM7:TR?= Mlj3V2FPT0WU
RH-1 Mn7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PERmlEPTB;MD6wN|gyQSEQvF2= M37RVHNCVkeHUh?=
NCI-H64 MonnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnkUXlqUUN3ME2wMlA{QDV5IN88US=> MnLDV2FPT0WU
EVSA-T M3XZdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlu3TWM2OD1yLkCzPVI{KM7:TR?= M{\uRnNCVkeHUh?=
KARPAS-299 NXzHUmh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGX0NZBKSzVyPUCuNFM6QCEQvF2= M1y2W3NCVkeHUh?=
MZ7-mel Mn;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGD4eVdKSzVyPUCuNFQxPCEQvF2= NG\LRZNUSU6JRWK=
LB373-MEL-D MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLtTWM2OD1yLkC0NVA2KM7:TR?= NYntfoxwW0GQR1XS
HEL NFjZ[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\lTWNKSzVyPUCuNFQyPCEQvF2= NHrHe5pUSU6JRWK=
SW872 NFXjT5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfJW4Z6UUN3ME2wMlA1OjFizszN MVTTRW5ITVJ?
DU-4475 NHTpco9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwMESyOFQh|ryP M4fCNXNCVkeHUh?=
IST-SL2 M2DN[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfkPWM6UUN3ME2wMlA1Ojd3IN88US=> NFyyO5pUSU6JRWK=
NCI-H82 NISwNIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2riVGlEPTB;MD6wOFMxPyEQvF2= MkjzV2FPT0WU
LC4-1 Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTBwMESzOVEh|ryP NFfzdGlUSU6JRWK=
HDLM-2 M1i5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwMESzPVIh|ryP NV;qbmlsW0GQR1XS
MMAC-SF NVnJNZp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorVTWM2OD1yLkC0OVM1KM7:TR?= MmfyV2FPT0WU
L-540 MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPNb4g4UUN3ME2wMlA1PjN7IN88US=> M4PGOHNCVkeHUh?=
MZ2-MEL M1\NVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwMES3OFIh|ryP M3vhU3NCVkeHUh?=
LU-134-A NInOdoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnEXXVlUUN3ME2wMlA1Pzd|IN88US=> M3vRVHNCVkeHUh?=
UACC-257 MlLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEGzbYNKSzVyPUCuNFQ5PDlizszN NHm1OFlUSU6JRWK=
NCI-H1581 MmL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTOTWM2OD1yLkC0PVU{KM7:TR?= M3rHc3NCVkeHUh?=
NB17 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnmTWM2OD1yLkC0PVc6KM7:TR?= MWnTRW5ITVJ?
SBC-1 M4H2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwMEWwOFIh|ryP NXj6d4VoW0GQR1XS
TALL-1 NEnyPYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1u1VGlEPTB;MD6wOVA1PSEQvF2= MYPTRW5ITVJ?
NCI-H1304 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfmVZdUUUN3ME2wMlA2OjB6IN88US=> NUX3U2V5W0GQR1XS
NEC8 MlP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\FTWM2OD1yLkC1Nlg3KM7:TR?= Ml\XV2FPT0WU
CAL-148 M2PBcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwMEW0N|kh|ryP MYPTRW5ITVJ?
CGTH-W-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwMEW0OFkh|ryP NF3HNVZUSU6JRWK=
NCI-H889 M{\wTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfpXFBKSzVyPUCuNFU2QTJizszN MV\TRW5ITVJ?
GR-ST MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTBwMEW2NlEh|ryP NGjmZ|ZUSU6JRWK=
KARPAS-422 NEm3So9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nFOGlEPTB;MD6wOVY2KM7:TR?= MW\TRW5ITVJ?
RPMI-8866 NI\KV3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwMEW3NVIh|ryP MVrTRW5ITVJ?
SCLC-21H MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nZ[WlEPTB;MD6wOVg5PCEQvF2= M1fRbnNCVkeHUh?=
COR-L88 M1XYVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTBwMEW5Nlch|ryP NV3yN29vW0GQR1XS
LU-139 NFywWG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M330U2lEPTB;MD6wOVk5PiEQvF2= M2HxOnNCVkeHUh?=
SF126 M1TrXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwME[xN|Mh|ryP NXLETpJZW0GQR1XS
NCI-H1882 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHy0OGtKSzVyPUCuNFY1OjRizszN MWDTRW5ITVJ?
EW-24 Mn7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfNbmd5UUN3ME2wMlA3PDh|IN88US=> M3TCZnNCVkeHUh?=
CP67-MEL MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jKb2lEPTB;MD6wOlgyKM7:TR?= M3rX[nNCVkeHUh?=
DG-75 M{nHTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPueW5KSzVyPUCuNFY5QTlizszN M4XKOXNCVkeHUh?=
LOXIMVI NXfjTWVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXyyZ2d4UUN3ME2wMlA4ODJ6IN88US=> NGLGeWpUSU6JRWK=
HH Moj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjxTWM2OD1yLkC3NVU4KM7:TR?= MoPYV2FPT0WU
K5 MormS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXL1OFR2UUN3ME2wMlA4OjJ4IN88US=> M2\ad3NCVkeHUh?=
EC-GI-10 MlvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTBwMEeyOVch|ryP MVHTRW5ITVJ?
SK-N-DZ MoDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PReWlEPTB;MD6wO|MxPyEQvF2= M{Lu[nNCVkeHUh?=
A3-KAW NWLsWVBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHve3VvUUN3ME2wMlA4OzVzIN88US=> MUnTRW5ITVJ?
MLMA MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DmNGlEPTB;MD6wO|Q3PSEQvF2= MXzTRW5ITVJ?
LB996-RCC MoHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3Wc4VKSzVyPUCuNFc4ODdizszN M1P3W3NCVkeHUh?=
OS-RC-2 M33zU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLSO3NrUUN3ME2wMlA4PzR6IN88US=> NYPtSo1UW0GQR1XS
CTB-1 NHzJS2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3n4emlEPTB;MD6wO|gyKM7:TR?= NX[5SFlHW0GQR1XS
IST-MES1 NXjaenVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwMEe5NVIh|ryP NWi3PVExW0GQR1XS
LS-1034 NXO1Sox[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvMT21WUUN3ME2wMlA5ODN3IN88US=> MXvTRW5ITVJ?
HT MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XXNGlEPTB;MD6wPFA5PiEQvF2= NUDrNIlMW0GQR1XS
NCI-H2141 MnjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4r6WGlEPTB;MD6wPFEh|ryP M2rO[nNCVkeHUh?=
LB2518-MEL MmLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLvfYNZUUN3ME2wMlA5OTRzIN88US=> M1y2VHNCVkeHUh?=
GI-ME-N MkPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIqzb5dKSzVyPUCuNFg1PTJizszN MV;TRW5ITVJ?
TGW MnfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEezPWZKSzVyPUCuNFg3ODdizszN NX75PII1W0GQR1XS
SK-NEP-1 M3ruWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3vc5hwUUN3ME2wMlA5PjRzIN88US=> NG\a[ZpUSU6JRWK=
NOMO-1 M3XuUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zRcGlEPTB;MD6wPVI4PSEQvF2= NETQPHBUSU6JRWK=
ES6 Mn;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4r2SGlEPTB;MD6wPVU5QSEQvF2= NITxPFdUSU6JRWK=
NCI-H209 MlzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TCZ2lEPTB;MD6wPVc5PiEQvF2= NEH1Rm5USU6JRWK=
GAK MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljZTWM2OD1yLkGwNVYh|ryP NYP1bINNW0GQR1XS
BC-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnn0TWM2OD1yLkGwN|YyKM7:TR?= M3;aTHNCVkeHUh?=
KLE MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTBwMUC0OFMh|ryP NFfEW2FUSU6JRWK=
EW-3 NEWzdWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTBwMUC5PEDPxE1? M{G5WHNCVkeHUh?=
NKM-1 NGHJOZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGP4VVFKSzVyPUCuNVEyKM7:TR?= NGfxPHdUSU6JRWK=
D-336MG NWjlOmJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXP5XG01UUN3ME2wMlEyOjR2IN88US=> NELnVVhUSU6JRWK=
NB69 MkDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLJW2w4UUN3ME2wMlEyOzBzIN88US=> MU\TRW5ITVJ?
D-263MG NW\rSnA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjITWM2OD1yLkGxO|EzKM7:TR?= MUfTRW5ITVJ?
KP-N-YS NVvxc|VyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXzN3NKSzVyPUCuNVIzQTFizszN NFS3To1USU6JRWK=
NCI-H1155 NVPiSoRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIO2dlVKSzVyPUCuNVI2PThizszN NYXPb41vW0GQR1XS
BOKU NIjqcIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXmSVl5UUN3ME2wMlEzPTd7IN88US=> MmTYV2FPT0WU
LAMA-84 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnkTWM2OD1yLkGyPVkh|ryP NYP4Um1TW0GQR1XS
Raji M4DHNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvaTWM2OD1yLkGzNVE4KM7:TR?= NX\SNFJRW0GQR1XS
LU-65 NHrhS5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUG0Z2JQUUN3ME2wMlE{OzB5IN88US=> NGHNNplUSU6JRWK=
NCI-H187 MlzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nuXWlEPTB;MD6xN|kzPCEQvF2= NYTIVYFJW0GQR1XS
GCIY M2OzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3JTWM2OD1yLkG0PVAyKM7:TR?= NWf6VGU4W0GQR1XS
NCI-H2107 MkfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLxdHpKSzVyPUCuNVUxQCEQvF2= NHzBNZRUSU6JRWK=
NCI-H1522 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLB[WZwUUN3ME2wMlE2OjZ4IN88US=> MlzZV2FPT0WU
NB6 NYXzNZRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPoeItKSzVyPUCuNVU3OjNizszN MULTRW5ITVJ?
EM-2 M1PCW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLKbGE3UUN3ME2wMlE2PzB4IN88US=> NYPCb4hQW0GQR1XS
HCC2218 NEjpZ49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLnTWM2OD1yLkG1PVgh|ryP NIfIUWlUSU6JRWK=
NCI-H748 M1XzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjM[2k6UUN3ME2wMlE3Ozd4IN88US=> NFzQW|JUSU6JRWK=
MS-1 NGPWNW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwMU[1N|ch|ryP M12xdXNCVkeHUh?=
NB5 M4\PeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XzZWlEPTB;MD6xOlU6PyEQvF2= NYLRXVduW0GQR1XS
OMC-1 NUfS[XFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jRXmlEPTB;MD6xOlY5QCEQvF2= NYTwc4pUW0GQR1XS
NCI-H345 M1PiZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwMU[5Nlgh|ryP MlTtV2FPT0WU
L-428 M3;pT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPiXopTUUN3ME2wMlE3QTR3IN88US=> M3\hPHNCVkeHUh?=
SCH NULnbodZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXXTWM2OD1yLkG4Olg2KM7:TR?= NWnVR4NGW0GQR1XS
NCI-H1417 MoXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzScYVKSzVyPUCuNVkzOjdizszN NYHPWoo6W0GQR1XS
COLO-320-HSR NIrnOWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TBV2lEPTB;MD6xPVU{OiEQvF2= NUn5WnBCW0GQR1XS
BT-474 M3i2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnHcYd2UUN3ME2wMlIxQDl{IN88US=> NWLlUldlW0GQR1XS
GDM-1 NXq0b3YxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\3fY51UUN3ME2wMlIyQTdzIN88US=> MkfrV2FPT0WU
NCI-H2196 NVS0c5JDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HKNWlEPTB;MD6yNlI{PSEQvF2= NEDDc49USU6JRWK=
KP-N-RT-BM-1 NXzBdJRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwMkKzOFkh|ryP MY\TRW5ITVJ?
KNS-81-FD MkTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLvTWM2OD1yLkKyPVU5KM7:TR?= NVP5W3p7W0GQR1XS
COLO-668 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljpTWM2OD1yLkKzOlc2KM7:TR?= M4DHU3NCVkeHUh?=
C2BBe1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEj4R5dKSzVyPUCuNlY4PDdizszN NEnQWIFUSU6JRWK=
Ramos-2G6-4C10 MnnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XxfmlEPTB;MD6yOlk2PCEQvF2= NHS5WnNUSU6JRWK=
CAS-1 MnThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2i2PWlEPTB;MD6yO|A6PiEQvF2= M4fDR3NCVkeHUh?=
GOTO MmX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXpSmRRUUN3ME2wMlI4QDl2IN88US=> NWfLN|NKW0GQR1XS
LP-1 M1TCZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHjWHJzUUN3ME2wMlI5ODV5IN88US=> MlvDV2FPT0WU
NCI-SNU-1 Ml\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7CO4NKSzVyPUCuNlk1OjJizszN M1LXO3NCVkeHUh?=
EB-3 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjLdZdKSzVyPUCuNlk6PzlizszN NUT6XmhjW0GQR1XS
MHH-NB-11 NIL3[3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrUb3A1UUN3ME2wMlMxPDB{IN88US=> MXPTRW5ITVJ?
SK-N-FI MlrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjaUHhKSzVyPUCuN|E3QTJizszN M3jhWHNCVkeHUh?=
HCC2157 M1X0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmC3TWM2OD1yLkOzPVE{KM7:TR?= MUnTRW5ITVJ?
SIMA MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULCZ3VDUUN3ME2wMlM1PThzIN88US=> Ml7oV2FPT0WU
MDA-MB-134-VI M3zEemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTJPIpNUUN3ME2wMlM3QTJ6IN88US=> NWDSeI1UW0GQR1XS
NCI-H1694 MnTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnMNoRKSzVyPUCuN|ch|ryP NXPvTWVrW0GQR1XS
EHEB M{jySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwM{mwPFUh|ryP NYfDUnhRW0GQR1XS
U-266 NIjaUG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4X3Z2lEPTB;MD6zPVg1PiEQvF2= NFjtRmhUSU6JRWK=
LC-1F NEnvVXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPCeIhKSzVyPUCuOFM4PjVizszN NGTP[YxUSU6JRWK=
SHP-77 NH3ibnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDlZlRKSzVyPUCuOFc5PTVizszN Mn\XV2FPT0WU
LS-513 NGLoTplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLWTWM2OD1yLkS5N|A4KM7:TR?= MUjTRW5ITVJ?

多くの細胞株試験データを見る場合、クリックしてください

体内試験 The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]

お薦めの試験操作(参考用のみ)

細胞試験:

[1]

+ 展開
  • 細胞株: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
  • 濃度: 0.1-100 pM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.


    (参考用のみ)
動物試験:

[4]

+ 展開
  • 動物モデル: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
  • 製剤: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
  • 投薬量: 20 mg/kg
  • 投与方法: Administered via i.v.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます:
5% DMSO+5% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
2.5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 853.91
化学式

C47H51NO14

CAS No. 33069-62-4
保管
別名 NSC 125973

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02181634 Active, not recruiting Cholangiocarcinoma PrECOG, LLC.|Celgene Corporation December 9, 2014 Phase 2
NCT03047265 Active, not recruiting Nasopharyngeal Carcinoma Sun Yat-sen University February 4, 2017 Phase 2
NCT02779855 Not yet recruiting Breast Cancer|Ductal Carcinoma|Invasive Breast Carcinoma|Invasive Ductal Breast Carcinoma H. Lee Moffitt Cancer Center and Research Institute|Amgen April 30, 2017 Phase 1|Phase 2
NCT00001426 Completed Ovarian Neoplasm National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 3, 1995 Phase 2
NCT01419548 Withdrawn Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 29, 2011 Phase 1
NCT01051934 Completed Non-Small Cell Lung Cancer|Adenocarcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) December 29, 2009 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • 回答:

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • 質問2:

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • 回答:

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associatedシグナル伝達経路

相関Microtubule Associated製品

Tags: Paclitaxelを買う | Paclitaxel ic50 | Paclitaxel供給者 | Paclitaxelを購入する | Paclitaxel費用 | Paclitaxel生産者 | オーダーPaclitaxel | Paclitaxel化学構造 | Paclitaxel分子量 | Paclitaxel代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID